Abstract
The novel alkylating dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) was evaluated for acute toxicity and antitumor activity in mice, with melphalan as a reference. To determine a safe and tolerable dose for efficacy studies the acute toxicity following intravenous injection in the tail vein was monitored using a 14-day schedule with up to four doses. The highest tested dose, 25 μmoles/kg, was considered close to this level, with minor effects on body weight gain but significant effects on hematological parameters. Melphalan and J1 appeared equitoxic with no statistically significant differences.
Subsequently a mouse hollow fiber model was employed with subcutaneous implantation of fibers containing human tumor cells. Three different human tumor cell lines as well as two samples of primary human tumor cells (ovarian carcinoma and chronic lymphatic leukemia) were used as tumor models. At the dose level tested there was a marked and statistically significant decrease in both T-cell leukemia CCRF-CEM and small cell lung cancer NCI-H69 tumor cell growth and viability in response to J1 as compared with both placebo and melphalan treated groups. In primary ovarian carcinoma cells only J1 treatment resulted in significant tumor regression (net cell kill). In summary the results indicate that, despite an expected short half time in the blood circulation, the promising in vitro data from the previous studies of J1 seems translatable into the in vivo situation. At equal doses of alkylating units J1, compared to melphalan, was more active in the mouse hollow-fiber model, but showed similar general toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Furner RL, Brown RK: L-phenylalanine mustard (L-PAM): The first 25 years. Cancer Treat Rep 64 (4/5): 559–574, 1980
Demirer T, Uysal VA, Ayli M, Genc Y, Ilhan O, Koc H, Dagli M, Arat M, Gunel N, Fen T, Dincer S, Ustael N, Yildiz M, Ustun T, Seyrek E, Ozet G, Muftuoglu O, Akan H: High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: A retrospective evaluation. Bone Marrow Transplant 31(9): 755–761, 2003
Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Jr., Gajewski JL, Champlin RE: High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: A new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 82(3): 420–426, 2001
Larsson R, Dhar S, Ehrsson H, Nygren P, Lewensohn R: Comparison of the cytotoxic activity of melphalan with L-prolyl-m-Lsarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients. Br J Cancer 78(3): 328–335, 1998
Gullbo J, Dhar S, Luthman K, Ehrsson H, Lewensohn R, Nygren P, Larsson R: Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): Comparison with melphalan. Anticancer Drugs 14(8): 617–624, 2003
Gullbo J, Wickstrom M, Tullberg M, Ehrsson H, Lewensohn R, Nygren P, Luthman K, Larsson R: Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J Drug Target 11(6): 355–363, 2003
Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR: In vivocultivation of tumor cells in hollow fibers. Life Sci 57(2): 131–141, 1995
Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Nygren P, Kristensen J, Tholander B, Binderup L, Larsson R: In vivoactivity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients. Cancer Lett 162(2): 193–200, 2001
Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Freijs A, Hansen K, Larsson R: Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats. Cancer Chemother Pharmacol 46(6): 493–500, 2000
Gullbo J, Tullberg M, Vabeno J, Ehrsson H, Lewensohn R, Nygren P, Larsson R, Luthman K: Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives. Oncol Res 14(3): 113–132, 2003
Larsson R, Kristensen J, Sandberg C, Nygren P: Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50(2): 177–185, 1992
Csoka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P: Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 54(2): 163–170, 1994
Nygren P, Kristensen J, Jonsson B, Sundstrom C, Lonnerholm G, Kreuger A, Larsson R: Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 6(11): 1121–1128, 1992
Gullbo J, Wallinder C, Tullberg M, Lovborg H, Ehrsson H, Lewensohn R, Nygren P, Luthman K, Larsson R: Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): Comparison with its m-L-sarcolysin analogue P2. Mol Cancer Ther 2(12): 1331–1339, 2003
Ferrara F, Del Vecchio L, Mele G, Rametta V, Ronconi F, Montuori R: A new combination chemotherapy for advanced chronic lymphocytic leukemia (vincristine, cyclophosphamide, melphalan, peptichemio, and prednisone protocol). Cancer 64(4): 789–792, 1989
Paccagnella A, Tredese F, Salvagno L, Brandes A, Sileni VC, Daniele O, Fornasiero A, Fosser V, Nicoletto O, Maggino T, Fiorentino MV: Peptichemio in pretreated patients with ovarian cancer. Cancer Treat Rep 69(1): 17–20, 1985
Jiang JD, Zhang H, Li JN, Roboz J, Qiao WB, Holland JF, Bekesi G: High anticancer efficacy of L-proline-m-bis (2-chloroethyl) amino-L-phenylalanyl-L-norvaline ethyl ester hydrochloride (MF13) in vivo. Anticancer Res 21(3B): 1681–1689, 2001
Gullbo J, Wickström M, Tullberg M, Ehrsson H, Lewensohn H, Nygren P, Luthman K, Larsson R: Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J Drug Target 11(6): 355–363, 2003
Yagi MJ, Scanlon KJ, Chin SE, Holland JF, Bekesi JG: Multiple transport pathways for L1210 cells: Uptake of PTT. 119, a bifunctional alkylator with carrier amino acids. Chemotherapy 34(3): 235–247, 1988
Nakanishi T, Tamai I, Sai Y, Sasaki T, Tsuji A: Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer Res 57(18): 4118–4122, 1997
Gonzalez DE, Covitz KM, Sadee W, Mrsny RJ: An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res 58(3): 519–525, 1998
Dubowchik GM, Walker MA: Receptor-mediated and enzymedependent targeting of cytotoxic anticancer drugs. Pharmacol Ther 83(2): 67–123, 1999
Nygren P, Larsson R: Differential in vitrosensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators. Int J Cancer 48(4): 598–604, 1991
Phillips RM, Pearce J, Loadman PM, Bibby MC, Cooper PA, Swaine DJ, Double JA: Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: Implications for anticancer drug screening programs. Cancer Res 58(23): 5263–5266, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gullbo, J., Lindhagen, E., Bashir-Hassan, S. et al. Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo . Invest New Drugs 22, 411–420 (2004). https://doi.org/10.1023/B:DRUG.0000036683.10945.bb
Issue Date:
DOI: https://doi.org/10.1023/B:DRUG.0000036683.10945.bb